These latest findings are based on data from the VERDICT trial.

Researchers see their AI model as a way to improve patient access to important imaging exams. 

A team of cardiologists and radiologists explored the issue, sharing their findings in JAMA Cardiology.

“Importantly, the pattern of damage to the heart was variable, suggesting that the heart is at risk of different types of injury,” one researcher said. 

Intelerad Medical Systems has acquired Lumedx, an Oakland, California-based healthcare technology company focused on analytics and cardiovascular information systems. This is Intelerad’s third acquisition in the last seven months.

The guidance, published in full in the Journal of Cardiovascular Computed Tomography, includes updates to previous CCTA recommendations and was designed to answer common questions.

The algorithm can help physicians make key decisions about a patient’s health, including whether or not it is time to consider statin therapy. 

The mandate goes into effect on April 1.